- Earnings roundup: Molson Coors profit skids on combination costs, Adidas earnings grow (Canadian Business)
August 5, 2008 - 10:41 a.m. FRANKFURT, Germany (AP) ? Sportswear maker Adidas AG said Tuesday its second-quarter net profit rose 12 percent from last year on increased demand for its products during the European 2008 football tournament and on Olympic-related merchandise.
- Acorda Therapeutics Reports Second Quarter 2008 Financial Results (Centre Daily Times)
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the second quarter of 2008.
- Earnings roundup: Molson Coors, Adidas (AP via Yahoo! Finance)
Molson Coors says its second quarter profit dropped 56 percent due to higher costs and charges associated with combining the company's U.S. arm with the maker of Miller beers.
- Acorda Therapeutics, Inc. Announces Exercise of Option by Underwriter (Business Wire via Yahoo! Finance)
HAWTHORNE, N.Y.----Acorda Therapeutics, Inc. announced today that Deutsche Bank Securities Inc., as underwriter of the Company?s common stock offering that was announced on August 7, 2008, has exercised its entire option to purchase an additional 600,000 shares of common stock at the public offering price of $28.50 per share.
- Acorda Therapeutics' Preclinical Pipeline Named One of the 10 Most Promising Neuroscience Projects Available for ... (Business Wire via Yahoo! Finance)
HAWTHORNE, N.Y.----Acorda Therapeutics, Inc. today announced that the Company?s preclinical pipeline has been selected by Windhover Information and an independent neuroscience expert as one of the top 10 most interesting neuroscience projects in development available for strategic partnering.
- Business in the Burbs: Prestige earnings drop on declining sales of several products (The Journal News)
Prestige Brands Holdings Inc., the Irvington company that markets Comet cleanser, Murine eye and ear drops and Prell shampoo, said earnings in the first quarter of its 2008 fiscal year dropped 6.5 percent to $7.8 million, or 16 cents a share.
- Acorda Therapeutics, Inc. Announces Exercise of Option by Underwriter (Centre Daily Times)
Acorda Therapeutics, Inc. (NASDAQ: ACOR) (the "Company") announced today that Deutsche Bank Securities Inc., as underwriter of the Company's common stock offering that was announced on August 7, 2008, has exercised its entire option to purchase an additional 600,000 shares of common stock at the public offering price of $28.50 per share. The exercise of the option increases the size of the ...